Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

試行錯誤による試行錯誤.

Leonard W Seymour,

    Lancet (London, England)
    |May 10, 2003
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    T cell engagers: expanding horizons in oncology and beyond.

    British journal of cancer·2025
    Same author

    The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response.

    Heliyon·2024
    Same author

    Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.

    Journal for immunotherapy of cancer·2024
    Same author

    AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes.

    Scientific reports·2023
    Same author

    Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

    Journal for immunotherapy of cancer·2023
    Same author

    Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

    Nature communications·2022
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    関連記事をすべて見る